Does oxidative stress and lipid peroxidation drive a self-reinforcing cycle of inflammation and insulin resistance in MASLD?

The progression of metabolic-associated steatotic liver disease (MASLD) is characterized by a complex, self-perpetuating pathological cycle. Research indicates that this process is driven by the interaction between metabolic dysfunction, oxidative stress, and inflammatory signaling, which collectively accelerate liver damage.

Mechanistic explanations

• Oxidative stress and lipid peroxidation: In the presence of hepatic lipid overload, free fatty acids (FFAs) serve as substrates for lipid peroxidation. This process, driven by mitochondrial dysfunction and NADPH oxidase, generates reactive oxygen species (ROS) that overwhelm cellular antioxidant defenses, such as the Nrf2 pathway.
• Inflammatory amplification: Lipid peroxidation products, including oxidized LDL (oxLDL), act as potent triggers for pro-inflammatory pathways. These products activate transcription factors such as NF-κB and JNK, stimulating the release of cytokines like TNF-α and IL-6. This response is often exacerbated by the gut-liver axis, where intestinal dysbiosis further fuels ROS production through TLR4 activation.
• Exacerbation of insulin resistance: The activation of JNK and NF-κB pathways directly impairs insulin signaling. These pathways induce serine phosphorylation of insulin receptor substrates (IRS-1/2), inhibiting downstream Akt phosphorylation and worsening insulin resistance. Markers of oxidative stress, such as F2-isoprostanes, show a significant correlation with HOMA-IR levels, independent of body mass index.

Clinical implications

• Self-reinforcing cycle: The relationship between these factors is bidirectional rather than linear. Insulin resistance promotes lipid accumulation, which generates ROS; ROS then fuel the inflammation that further impairs insulin sensitivity.
• Progression to MASH: Once established, this triad of oxidative stress, inflammation, and insulin resistance creates a "vicious cycle" that facilitates the transition from simple steatosis to metabolic-associated steatohepatitis (MASH), fibrosis, and chronic hepatocyte injury through pathways like apoptosis and ferroptosis.

Bottom line

The claim is strongly supported by mechanistic evidence; MASLD-associated lipid accumulation triggers a self-reinforcing loop where oxidative stress and inflammation mutually amplify each other and worsen insulin resistance, driving progressive liver injury.